Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function

PURPOSE: In two trials, the influences of hepatic and renal impairment on the pharmacokinetics of olodaterol, a novel long-acting inhaled β(2)-agonist for treatment of COPD, were investigated. SUBJECTS AND METHODS: The first trial included eight subjects with mild hepatic function impairment (Child–...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunz, Christina, Luedtke, Doreen, Unseld, Anna, Hamilton, Alan, Halabi, Atef, Wein, Martina, Formella, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807896/
https://www.ncbi.nlm.nih.gov/pubmed/27051282
http://dx.doi.org/10.2147/COPD.S94234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4807896/
https://www.ncbi.nlm.nih.gov/pubmed/27051282
http://dx.doi.org/10.2147/COPD.S94234

Ejemplares similares